None listed
Conditions
Interventions
Others(Early screening for cardiac amyloidosis via AI-ECG or CT-ECV) : The AI-enhanced electrocardiogram (AI-ECG) developed by Mayo Clinic is a tool that offers the potential for early, non-invasive s
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adults aged 19 years or older who have provided written informed consent (including consent from a legal representative in cases where voluntary consent is not feasible) 2) Patients with a documented history of atrial fibrillation (paroxysmal or persistent) and the presence of at least one "red-flag" symptom or sign. 3) Patients capable of undergoing at least one of the following diagnostic assessments: ? AI-ECG analysis based on standard 12-lead electrocardiogram data. ? Extracellular Volume (ECV) analysis derived from cardiac CT imaging.
Exclusion criteria
Exclusion criteria: 1) Patients with a prior diagnosis of cardiac amyloidosis (either AL or ATTR type). 2) Patients with severe heart failure (NYHA class IV) or those with a terminal illness and a life expectancy of less than one year. 3) Any other condition or situation that the investigator deems inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac amyloidosis detection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic sensitivity and specificity of AI-ECG alone, CT-ECV alone, and the combined model;Correlation analysis between AI-ECG/CT-ECV indices and biopsy findings, 99mTc-DPD scintigraphy, and serum/urine monoclonal protein assays in patients with confirmed cardiac amyloidosis | — |
Countries
Korea, Republic of
Contacts
Public ContactJuyoun Kim
Samsung Medical Center
Outcome results
None listed